Bosch Healthcare Solutions has teamed up with BioGX Inc. from the USA, a company producing innovative molecular reagents for DNA-/RNA-based tests. Goal of the collaboration between Bosch and BioGX is to develop and commercialize new tests for the Vivalytic molecular diagnostics platform. “With BioGX we are expanding our Vivalytic platform with an experienced and well-known biocontent partner that has had an excellent track record in the USA for over ten years,” says managing director of Bosch Healthcare Solutions GmbH, Marc Meier.
| Bosch Healthcare Solutions Press contact: Thomas Berroth Marketing & Communication Thomas.berroth2@de.bosch.com +4971181145599 www.bosch-vivalytic.com | BioGX Press contact: Robyn Martin Marketing & Communication +1.205.250.8055 www.biogx.com |
Bosch Healthcare Solutions GmbH is a wholly owned subsidiary of Robert Bosch GmbH. The subsidiary was established in 2015 with the aim of developing products and services that improve people’s health and quality of life. Nearly 300 associates (state 2024) are employed at the company’s headquarters in Waiblingen, Germany. The subsidiary’s solutions draw on the Bosch Group’s core competencies: sensors to collect data, software to evaluate that data, and services based on this data analysis.
Additional information is available online at www.bosch-healthcare.com, www.vivatmo.com, www.bosch-vivalytic.com.
About BioGX
BioGX, Inc., headquartered in Birmingham, Alabama, and its wholly owned subsidiary BioGX B.V., based in Amsterdam, The Netherlands, (collectively “BioGX”), develop and commercialize molecular diagnostics reagents across diverse applications. BioGX operates in a cGMP compliant environment certified to International Standard ISO 13485. The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms. The Sample-ReadyTM technology is at the core of all product offerings for Clinical, Food Safety, Pharma and Water Quality molecular testing. BioGX B.V.’s 50+ molecular diagnostic products are marketed and sold in 100+ countries through its Global Distribution Network.
The Bosch Group is a leading global supplier of technology and services. It employs roughly 417,900 associates worldwide (as of December 31, 2024). According to preliminary figures, the company generated sales of 90.5 billion euros in 2024. Its operations are divided into four business sectors: Mobility, Industrial Technology, Consumer Goods, and Energy and Building Technology. With its business activities, the company aims to use technology to help shape universal trends such as automation, electrification, digitalization, connectivity, and an orientation to sustainability. In this context, Bosch’s broad diversification across regions and industries strengthens its innovativeness and robustness. Bosch uses its proven expertise in sensor technology, software, and services to offer customers cross-domain solutions from a single source. It also applies its expertise in connectivity and artificial intelligence in order to develop and manufacture user-friendly, sustainable products. With technology that is “Invented for life,” Bosch wants to help improve quality of life and conserve natural resources. The Bosch Group comprises Robert Bosch GmbH and its roughly 470 subsidiary and regional companies in over 60 countries. Including sales and service partners, Bosch’s global manufacturing, engineering, and sales network covers nearly every country in the world. Bosch’s innovative strength is key to the company’s further development. At 136 locations across the globe, Bosch employs some 86,900 associates in research and development, of which nearly 48,000 are software engineers.
Additional information is available online at www.bosch.com, www.iot.bosch.com, www.bosch-press.com.
